Barry Greene, Sage CEO, at Endpoints #JPM23 (Adrien Villez for Endpoints News)
February 6, 2023 09:54 AM ESTUpdated 10:50 AM
FDA+

Sage, Bio­gen set their sights on a sum­mer PDU­FA dead­line as zu­ra­nolone de­ci­sion looms

John Carroll

Editor & Founder

Sage and its part­ners at Bio­gen can now mark a sum­mer date for a go/no go mar­ket­ing de­ci­sion for their block­buster de­pres­sion can­di­date, zu­ra­nolone. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times